Abstract
In clinical development of a test treatment, clinical trials are usually conducted to collect data for evaluation of safety and efficacy of the test treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study designs are necessarily conducted. The clinical trial process is lengthy and costly, consisting of protocol development, trial conduct, data collection, statistical analysis and interpretation, and reporting. In practice, some controversial issues are commonly encountered regardless of compliance with good clinical practice. These issues include, but are not limited to, statistical hypotheses for clinical evaluation, instability of classical sample size calculation, integrity of blinding, clinical strategy for endpoint selection, impact of protocol amendments, flexibility and feasibility of adaptive design methods, multiplicity in clinical trials, and independence of data monitoring committees. In this article, these issues are briefly outlined. The impact of these issues on the evaluation of the safety and efficacy of the test treatment under investigation is assessed and discussed with examples whenever applicable. Recommendations regarding possible resolutions of these issues are also provided whenever possible.
Similar content being viewed by others
References
Chow SC, Shao J. Statistics in Drug Research. New York: Marcel Dekker; 2002.
Chow SC, Shao J. Analysis of clinical data with breached blindness. Stat Med. 2004;23:1185–1193.
Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM. Ascorbic acid for the common cold: a prophylactic and therapeutic trial. J Am Med Assoc. 1975;231:1038–1042.
Chow SC, Shao J, Hu YP. Assessing sensitivity and similarity in bridging studies. J Biopharm Stat. 2002;12:385–400.
Chow SC, Shao J. Inference for clinical trials with some protocol amendments. J Biopharm Stat. 2005;15:659–666.
Chow SC, Chang M, Pong A. Statistical consideration of adaptive methods in clinical development. J Biopharm Stat. 2005;15:575–591.
US Food and Drug Administration. Draft guidance for industry: adaptive design clinical trials for drug and biologics. Rockville, MD: US FDA: 2010.
Chang M. Adaptive design method based on sum of p-values. Stat Med. 2007;26:2772–2784.
Cheng B, Chow SC. Statistical inference for a multiple-stage transitional seamless trial design with different study objectives and endpoints. Manuscript submitted for publication: 2010.
Westfall P, Bretz F. Multiplicity in clinical trials. In: Chow SC, ed. Encyclopedia of Biopharmaceutical Statistics, 3rd ed. New York: Taylor & Francis: 2010.
International Conference on Harmonization. Guideline E9. Statistical principles for clinical trials. CPMP/ICH/363/96. 1998. http://www.emea.europa.eu/pdfs/human/ich/036396en.pdf.
European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. EMEA Doc. Ref. CHMP/EWP/2459/02. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf.
Marcus R, Peritz E, Gabriel KB. On closed testing procedures with special reference to ordered analysis of variance. Biometrika. 1976:63:655–660.
Shao J, Chow SC. Reproducibility probability in clinical trials. Stat Med. 2002;21:1727–1742.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chow, SC., Yang, LY. & Lu, Y. Some Controversial Issues in Clinical Trials. Ther Innov Regul Sci 45, 163–174 (2011). https://doi.org/10.1177/009286151104500211
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286151104500211